RxDoctor Payments Data

Mark Mahloch, MD

Family Medicine · Valley, NENPI 1144338872

Payments from drug & device makers

$6,359in general payments, 2019–2025

Across 412 payments — averaging $15.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$898
  • Novo Nordisk$667
  • Boehringer Ingelheim$488
  • Lilly USA, LLC$462
  • Pfizer$422
  • AstraZeneca$414
  • plus $3K from 41 others

What the payments were for

  • Food & beverage$6,353100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,359 in reported general payments places this provider in the 90th percentile of 981 family medicine providers in Nebraska.

See all family medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$116,681
Medicare patients
220
Services billed
2,425

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide72$90,062
EliquisApixaban67$84,447
OzempicSemaglutide59$68,713
JardianceEmpagliflozin45$53,866
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$39,580
XareltoRivaroxaban19$30,219
Tresiba Flextouch U-200Insulin Degludec39$24,540
FarxigaDapagliflozin Propanediol21$20,445
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog27$15,177
BelsomraSuvorexant30$13,964
LinzessLinaclotide22$13,360
Breo ElliptaFluticasone/Vilanterol17$11,395
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$9,268
EntrestoSacubitril/Valsartan13$8,965
Fiasp FlextouchInsulin Aspart (Niacinamide)16$8,607

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$462$90,06272 claims
PfizerEliquis$422$84,44767 claims
Novo NordiskOzempic$667$68,71359 claims
Boehringer IngelheimJardiance$488$53,86645 claims
GSKTrelegy Ellipta, Breo Ellipta$34$50,97563 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$414$35,11549 claims
Johnson & JohnsonXarelto$275$30,21919 claims
MerckBelsomra$91$13,96430 claims
AbbVieLinzess$898$13,36022 claims
NovartisEntresto$135$8,96513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 981 family medicine providers in Nebraska.

Other family medicine in Valley

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →